A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK.

Johansen P, Sandberg A, Capehorn M

Open source

DOI
10.1007/s12325-020-01242-z
Published
2020 Mar
Container
Advances in therapy
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s12325-020-01242-z,
  title = {A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK.},
  author = {Johansen P and Sandberg A and Capehorn M},
  year = {2020},
  journal = {Advances in therapy},
  doi = {10.1007/s12325-020-01242-z},
  url = {https://doi.org/10.1007/s12325-020-01242-z}
}

RIS

TY  - JOUR
TI  - A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK.
AU  - Johansen P
AU  - Sandberg A
AU  - Capehorn M
PY  - 2020
JO  - Advances in therapy
DO  - 10.1007/s12325-020-01242-z
UR  - https://doi.org/10.1007/s12325-020-01242-z
ER  - 

APA

P, J., A, S., & M, C. (2020). A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK.. Advances in therapy. https://doi.org/10.1007/s12325-020-01242-z

Source records